Volume 74, Issue 1, Pages (July 2018)

Slides:



Advertisements
Similar presentations
Pascal Rischmann  European Urology Supplements 
Advertisements

The PSA Era is not Over for Prostate Cancer
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis  Maria I. Carlo, Darren R.
Volume 58, Issue 2, Pages (August 2010)
Volume 63, Issue 2, Pages (February 2013)
Volume 70, Issue 1, Pages (July 2016)
Volume 63, Issue 6, Pages (June 2013)
Renal Cell Carcinoma: Prognostic Factors and Patient Selection
Volume 70, Issue 5, Pages (November 2016)
Volume 51, Issue 1, Pages (January 2007)
Volume 50, Issue 5, Pages (November 2006)
Histologic Grading of Noninvasive Papillary Urothelial Neoplasms
Volume 71, Issue 6, Pages e171-e172 (June 2017)
Let the Games Begin (with EAU Approval)
Volume 68, Issue 1, Pages (July 2015)
Prostate Cancer Epidemic in Sight?
Volume 70, Issue 3, Pages (September 2016)
Bladder Cancer: A Major Public Health Issue
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey  John B. McKinlay, Carol L. Link  European.
Volume 54, Issue 4, Pages (October 2008)
Volume 54, Issue 4, Pages (October 2008)
Volume 61, Issue 5, Pages (May 2012)
Volume 52, Issue 5, Pages (November 2007)
Volume 72, Issue 4, Pages (October 2017)
Volume 68, Issue 1, Pages 5-7 (July 2015)
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
Volume 66, Issue 5, Pages (November 2014)
Volume 68, Issue 1, Pages (July 2015)
Volume 70, Issue 1, Pages (July 2016)
Volume 60, Issue 5, Pages (November 2011)
International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia  Brett Delahunt, John R. Srigley, Lars Egevad,
Volume 56, Issue 6, Pages (December 2009)
Prostate Cancer Epidemic in Sight?
Volume 65, Issue 6, Pages (June 2014)
The PSA Era is not Over for Prostate Cancer
Volume 50, Issue 3, Pages (September 2006)
Volume 61, Issue 6, Pages (June 2012)
Volume 64, Issue 4, Pages (October 2013)
Global Burden of Urologic Cancers, 1990–2013
Volume 74, Issue 3, Pages (September 2018)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 66, Issue 6, Pages (December 2014)
Volume 51, Issue 5, Pages (May 2007)
Volume 63, Issue 3, Pages (March 2013)
Trends in Hypospadias Surgery: Results of a Worldwide Survey
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 59, Issue 1, Pages (January 2011)
Volume 52, Issue 1, Pages (July 2007)
The Economic Costs of Overactive Bladder in Germany
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 74, Issue 5, Pages (November 2018)
Testicular Cancer Variations in Time and Space in Europe
Volume 63, Issue 2, Pages (February 2013)
Prognostic Impact of Comorbidity in Patients with Bladder Cancer
Sergio Bracarda  European Urology Supplements 
European Urology is “Your” Journal
Economic Burden of Bladder Cancer Across the European Union
Volume 52, Issue 4, Pages (October 2007)
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Annika Berntsen, Poul F. Geertsen, Inge Marie Svane  European Urology 
Joaquim Bellmunt  European Urology Supplements 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Jan Roigas  European Urology Supplements 
Pathology and Molecular Pathogenesis of Renal Cell Carcinoma
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 74, Issue 1, Pages 124-128 (July 2018) Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma  Sumanta K. Pal, Paulo Bergerot, Nazli Dizman, Cristiane Bergerot, Jacob Adashek, Russell Madison, Jon H. Chung, Siraj M. Ali, Jeremy O. Jones, Ravi Salgia  European Urology  Volume 74, Issue 1, Pages 124-128 (July 2018) DOI: 10.1016/j.eururo.2018.03.032 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Pathology and radiographic findings for patients 1–3 with mPRCC with EML4-ALK rearrangement. mPRCC=metastatic papillary renal cell carcinoma. European Urology 2018 74, 124-128DOI: (10.1016/j.eururo.2018.03.032) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Trend in tumor burden (based on the sum of longest dimension of index lesions) and associated systemic therapies rendered for (A) patient 1, (B) patient 2, and (C) patient 3 with mPRCC with EML4-ALK rearrangement. mPRCC=metastatic papillary renal cell carcinoma; PD=progressive disease; PR=partial response; SD=stable disease. European Urology 2018 74, 124-128DOI: (10.1016/j.eururo.2018.03.032) Copyright © 2018 European Association of Urology Terms and Conditions

European Urology 2018 74, 124-128DOI: (10.1016/j.eururo.2018.03.032) Copyright © 2018 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.